Press Releases

 
Press Releases
  Date Title View
Feb 29, 2016
- Company to hold conference call at 8:30am ET today -- Survival and other key data from AdVise and matched controls to be reviewed with regulators in Summer 2016 - DURHAM, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, t...
Feb 22, 2016
DURHAM, N.C., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, February 29, 2016 at 8:30 a.m. ET to report financial results for the fourth quarter ...
Feb 20, 2016
Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting Despite Trial Not Meeting Primary Endpoint Company to Host Conference Call on February 22 at 8:00 a.m. EST to Provide Additional Analyses and Plans for Further Clinical Development DURHAM, N.C., Feb. 20, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical comp...
Feb 16, 2016
DURHAM, N.C., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that detailed results from the Company's Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT), will be present...
Feb 8, 2016
DURHAM, N.C., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today presented positive results from a pivotal study of its antiviral, brincidofovir, in an animal model for smallpox at the ASM Biodefense and Emerging Diseases Research Meeti...
Jan 5, 2016
DURHAM, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday...
Dec 28, 2015
- SUPPRESS Did Not Achieve Primary Endpoint for Prevention of Clinically Significant CMV Infection After HCT - - Detailed Data Analysis to Follow - - Company to Hold Conference Call Today at 8:30 a.m. ET - DURHAM, N.C., Dec. 28, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals i...
Nov 24, 2015
DURHAM, N.C., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday...
Nov 11, 2015
DURHAM, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, and W. Garrett Nichols, M.D., M.S., Chief Medical Officer, will present at the...
Nov 5, 2015
Topline Data from SUPPRESS Trial of Brincidofovir for Prevention of Cytomegalovirus in Hematopoietic Cell Transplant Recipients Anticipated in Early 2016 Dosing Initiated in Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients DURHAM, N.C., Nov. 5, 2015 (GLOBE ...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase